目的 探究丁苯酞軟膠囊聯(lián)合依達拉奉治療神經(jīng)功能障礙的臨床療效。方法 選擇2017年1月—2019年1月于西安大興醫(yī)院神經(jīng)內(nèi)科接受治療的98例神經(jīng)功能障礙的患者為研究對象，按照隨機數(shù)字表法將患者均分為對照組和觀察組，每組各49例。對照組患者靜滴依達拉奉注射液，應(yīng)用劑量為30 mg/次，2次/d。觀察組在對照組基礎(chǔ)上口服丁苯酞軟膠囊，2粒/次，3次/d。兩組患者治療2周。觀察兩組患者的臨床療效，同時比較兩組治療前后的美國國立衛(wèi)生研究院卒中量表（NIHSS）評分、Barthel指數(shù)及簡易智能精神狀態(tài)量表（MMSE）評分。結(jié)果 治療后，觀察組治療總有效率為93.88%，對照組的治療總有效率為83.67%，兩組對比差異存在統(tǒng)計學意義（P<0.05）。經(jīng)治療1周及2周后，兩組患者NIHSS量表評分較治療前顯著下降（P<0.05），且觀察組患者NIHSS評分顯著均低于對照組（P<0.05）。治療后，兩組患者Barthel指數(shù)和MMSE量表評分均顯著提升（P<0.05），且觀察組患者Barthel指數(shù)及MMSE評分均顯著高于對照組（P<0.05）。結(jié)論 丁苯酞聯(lián)合依達拉奉對于神經(jīng)功能障礙有較好的治療效果，能顯著改善患者的神經(jīng)功能和生活質(zhì)量，且不良反應(yīng)的發(fā)生率較低，值得進行臨床推廣。

Objective To explore the clinical effect of Butylphthalide Soft Capsules combined with edaravone in treatment of neurological dysfunction. Methods A total of 98 patients with neurological dysfunction who were treated in the Department of Neurology, Xi'an Daxing Hospital from January 2017 to January 2019 were selected as the study subjects. According to the random number table method, the patients were divided into the control group and the observation group, with 49 patients in each group. Patients in the control group were iv administered with Edaravone Injection at doses of 30 mg/time, twice daily. Patients in the observation group were po administered with Butylphthalide Soft Capsules on the basis of control group, two grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy in two groups was observed, and the NIHSS score, Barthel index, and MMSE score before and after treatment were compared. Results After treatment, the total effective rate was 93.88% in the observation group, and 83.67% in the control group, with statistically significant difference between two groups (P<0.05). After one and two weeks of treatment, the NIHSS scale score in two groups was significantly lower than that before treatment (P<0.05), and the NIHSS score in the observation group was significantly lower than that of the control group (P<0.05). After treatment, the Barthel index and MMSE scale score in two groups were significantly improved (P<0.05), and the Barthel index and MMSE score in the observation group were significantly higher than those in the control group (P<0.05). Conclusion Butylphthalide combined with edaravone has a good therapeutic effect on neurological dysfunction, can significantly improve the neurological function and quality of life of patients, and the incidence of adverse reactions is low, which is worthy of clinical promotion.

R971